AGIO:NSD-Agios Pharm (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 45.61

Change

0.00 (0.00)%

Market Cap

USD 2.59B

Volume

2.20M

Analyst Target

USD 65.45
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.95B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing AGIO

WDNA 2.46 % 0.00 %

N/A

N/A
WDNA:LSE WisdomTree BioRevolution .. 2.44 % 0.00 %

N/A

N/A
WBIO:LSE WisdomTree BioRevolution .. 2.35 % 0.00 %

N/A

USD 3.87M
WRNA:XETRA WisdomTree BioRevolution .. 2.28 % 0.00 %

N/A

USD 2.77M
ETHO Amplify ETF Trust 0.57 % 0.45 %

N/A

USD 0.18B
AVSC American Century ETF Trus.. 0.35 % 0.00 %

N/A

USD 1.34B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 104.80% 64% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 104.80% 64% D 81% B-
Trailing 12 Months  
Capital Gain 84.28% 58% F 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 84.28% 58% F 79% B-
Trailing 5 Years  
Capital Gain 35.78% 54% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.78% 54% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain -1.26% N/A N/A 40% F
Dividend Return -1.26% N/A N/A 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.11% N/A N/A 53% F
Risk Adjusted Return -3.59% N/A N/A 36% F
Market Capitalization 2.59B 91% A- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector